Lin28b Promotes Head and Neck Cancer Progression via Modulation of the Insulin-Like Growth Factor Survival Pathway

Nehad M. Alajez¹, Wei Shi², Dennis Wong³, Michelle Lenarduzzi²,³, John Waldron⁴,⁵, Ilan Weinreb⁶, Fei-Fei Liu²,³,⁴,⁵

¹ Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, Saudi Arabia
² Ontario Cancer Institute, Toronto, Canada
³ Department of Medical Biophysics, University of Toronto, Toronto, Canada
⁴ Department of Radiation Oncology, University Health Network, Toronto, Canada
⁵ Department of Radiation Oncology, University of Toronto, Toronto, Canada
⁶ Department of Pathology, University Health Network, Toronto, Canada

Correspondence to: Fei-Fei Liu, email: Fei-Fei.Liu@rmp.uhn.on.ca

Keywords: Lin28b, microRNA, Let-7, HNC, IGF

Received: December 04, 2012, Accepted: December 27, 2012, Published: December 29, 2012

ABSTRACT:

Lin28 is a developmentally regulated RNA binding protein which has recently emerged as key regulator in the biogenesis of the let-7 micro-RNA family. While the expression of Lin28b has been linked to advanced tumor stage, the precise molecular mechanism(s) by which Lin28b drives disease progression is still being unraveled. Herein, we generated a let-7-resistant Lin28b ORF, stably expressed in the FaDu head and neck cancer (HNC) cell line. FaDu-Lin28b cells exhibited enhanced tumor growth in vitro and in vivo. Global gene and micro-RNA expression analyses revealed significant enrichment in several pathways involved in cell migration, chromatin remodeling, and cellular stress response. Direct regulation of selected genes (HMGA2, CCND2, IGF1R, and IGF2BP2) via a let-7-Lin28b mechanism was validated. Notably, up-regulation of several genes in the IGF pathway in Lin28b-expressing cells was observed. Functional studies revealed significant increase in the survival of Lin28b-expressing cells when cultured under stress conditions, which was dependent on the presence of IGF1. Therefore, our data identified several novel gene targets for Lin28b-Let7, and revealed a novel mechanism by which Lin28b promote tumorigenesis. Concordantly, clinical examinations of Lin28b, IGF2BP2 and IGF2 revealed a significant association between the expression of these genes with disease relapse, thereby corroborating the potential relevance for the Lin28b/IGF axis in HNC progression.

INTRODUCTION

Lin28 is a developmentally regulated RNA binding protein which is expressed at high levels in undifferentiated embryonic stem cells (ESCs), but is dramatically reduced during differentiation [1]. Given its crucial role in maintaining the pluripotency of ESCs, this developmental regulator was subsequently found to be an integral member of the reprogramming gene set utilized to generate induced pluripotent stem cells (iPS)[2]. Shortly thereafter, Lin28 was also identified to function as a post-transcriptional regulator of Let-7 miRNA biogenesis, by inhibiting the microprocessor-mediated cleavage of pri-let-7 miRNAs [3]. Additionally, it could also induce uridylation of precursor let-7 (pre-let-7) at the 3’ end, thereby inhibiting processing by DICER [4]. Furthermore, Lin28-mediated poly-uridylation of pre-Let-7 miRNA was dependent on its interaction with the TUTase4 (TUT4) enzyme [5, 6]. Lin28 over-expressing transgenic mice exhibited increased body size, crown-rump length, and delayed onset of puberty, which in turn were associated with increased glucose metabolism and insulin sensitivity [7]. In addition to its role in stem cell biology and development, high expression of Lin28 has
also been associated with advanced stages in several different human malignancies [8, 9-12]. Not surprisingly, over-expression of Lin28 imparted radiation resistance properties mediated via K-ras regulation through a let-7 dependent mechanism [13]. Lin28 expression has also been linked to cancer stem cells [12, 14, 15].

Although the precise molecular mechanism(s) by which Lin28 drives tumorigenesis remains elusive, several cancer promoting genes (e.g. MYC, RAS, and HMG1-A2) have been reported to be direct targets for the let-7 miRNA family[16-18]. In this current study, we observed that over-expressing a let-7-resistant Lin28 gene in head and neck squamous cell carcinoma (HNSCC) was associated with enhanced tumour progression both in vitro and in vivo. Further investigations revealed significant suppression of Let-7 miRNA biogenesis in Lin28b-expressing tumor cells. Additionally, our study unravelled a novel molecular mechanism by which Lin28b promoted tumor survival under stress conditions through a let-7-IGF-dependent mechanism. Finally, in a cohort of 38 HNSCC patient tumour samples, over-expression of Lin28b, IGF2BP2, and IGF2 were observed to be associated with worse clinical outcome, strongly suggesting a role for the Lin28b-IGF pathway in contributing to HNSCC relapse.

RESULTS

Exogenous expression of Lin28b in FaDu cells promoted growth both in vitro and in vivo

Previous studies have reported significant association between Lin28b expression and advanced tumor stage; however, none of these studies examined the role of Lin28b in HNSCC [12-15]. Since Lin28b itself was subjected to Let-7 regulation, a Let-7-resistant Lin28b-expressing vector was constructed by cloning the Lin28b open reading frame (ORF), excluding the predicted Let-7 binding site in the 3’ UTR region, into the pIRES-hrGFP II mammalian expression vector using the indicated primers in Supplementary Table 1. Stable transfection of the FaDu HNSCC tumor cell line (which has low endogenous Lin28b expression) with this plasmid led to a significant increase in Lin28b expression at both the mRNA and protein levels in two selected stable clones (A1 and D1), compared to GFP-transfected control cells (Fig 1A and B). Unless indicated otherwise, all subsequent experiments were conducted using the FaDu Lin28b D1 clone. Since advanced tumor stage often present with metastases, the migration capacity of Lin28b transfected FaDu cells in vitro was compared to that of parental control cells. As shown in Figure 1C, FaDu Lin28b cells exhibited a significantly higher migration potential compared to the GFP-transfected cells by ~5-fold. Furthermore, FaDu Lin28b expressing cells also exhibited enhanced proliferation in vitro (Supplementary Fig 1), plus increased tumour growth and radiation resistance in vivo, compared to the parental line (Fig 1D).

Expression of Lin28b inhibited Let-7 miRNA biogenesis in FaDu Cells

Lin28b has previously been shown to inhibit Let-7 miRNA biogenesis post-transcriptionally through interaction with TUT4, and by mediating pre-Let-7 polyuridylation [5]. To examine whether Let-7 microRNAs (miRNAs) were subjected to Lin28 regulation in this tumor model, the NanoString NCounter platform was utilized for global quantification of miRNA expression in FaDu~Lin28b compared to FaDu~GFP cells. The resulting data revealed significant down-regulation of several members of the Let-7 family in the FaDu~Lin28b cells, corroborating that Lin28b was indeed targeting this family of miRNAs in these cells (Fig 2A). The expression level of two of the down-regulated miRNAs (miR-98, and Let-7g) was validated in the FaDu~Lin28b cells using single-well quantitative RT-PCR (Fig 2B).

Characterizing the downstream targets of Let-7 miRNAs in FaDu~Lin28b cells

In order to further examine the genes which were directly regulated by Let-7 miRNAs in FaDu~Lin28b cells, the same RNA preparation used for miRNA profiling was also subjected to global gene expression profiling using the Affymetrix HuGene-1_0-st-v1 array. Using 1.5-fold change as the cut-off, 324 genes were up-regulated in FaDu~Lin28b vs. FaDu~GFP cells (Fig 2C, FaDu Lin28b Up). Gene Ontology (GO) analysis on these 324 transcripts revealed significant enrichment in signal transduction, cell migration, and cellular response to insulin (Supplementary Table 2). These functions are consistent with the phenotype data of increased proliferation, migration and in vivo growth demonstrated in the FaDu~Lin28b cells (Fig 1C, 1D & Supplementary Fig 1). Since up-regulation of some of these genes in the FaDu~Lin28b cells could be induced indirectly or through a non-Let-7-dependent mechanism, a non-redundant list of predicted Let-7 gene targets was compiled using the TargetScan miRNA target prediction database. When the up regulated gene list from the FaDu~Lin28b cells was crossed with the list of in silico-predicted Let-7 targets, there was an overlap in 41 genes (Fig 2C). To focus on this group of genes which should be more relevant to HNSCC biology, this up regulated gene list from the FaDu~Lin28b cells, and the list of predicted Let-7 gene targets, was further cross-referenced with a third list of up-regulated genes in HNSCC identified by analyzing publicly available gene expression dataset from 22 HNSCC compared to 22 adjacent normal tissues (GSE6631). Using this
strategy, 5 genes were identified to be common to all three aforementioned gene lists: HMGA2, CCND2, IGF1R, PAK1, and GNS. The expression level of 3 of these 5 overlapping, plus several additional genes (DICER1, CCND2, HMGA2, IGF1R, IGF2BP2, HIST1H2BK, and ZCCHC9), were validated in both FaDu–Lin28b clones “A1” and “D1” using qRT-PCR (Fig 2D).

**Direct regulation of HMGA2, CCND2, IGF2BP2, and IGF1R by Let-7 miRNA**

The data thus far (Fig 2) suggested a direct regulation of several gene targets in FaDu–Lin28b cells via a Lin28b-Let-7 mechanism. To confirm that these genes were indeed targeted by Let-7 miRNAs, we constructed several reporter vectors carrying the predicted binding site(s) downstream of a firefly luciferase gene in the pMIR-Report vector as previously described [19] (Fig 3A). IGF2BP2 contains two predicted Let-7 binding sites; IGF1R and CCND2 each harbours three predicted Let-7 binding sites, while HMGA2 has six predicted Let-7 binding sites. For each construct, a mutant version of the reporter vectors in which the predicted Let-7 seed region(s) in the 3' UTRs was also generated using the primer combination listed in Supplementary Table 1. A positive and negative control reporter construct carrying

![Figure 1: Stable expression of Lin28b enhanced HNSCC tumorigenicity in vitro and in vivo.](image-url)

Expression of Lin28b in FaDu cells stably transfected with Lin28b-expression vector was detected by (A) qRT-PCR; and (B) Western blotting (27 kd), using GAPDH (37 kd) for loading control. (C) Representative images depicting enhanced migration ability of FaDu–Lin28b cells compared FaDu–GFP cells. Data were presented as mean ± S.E, n=10. (D) FaDu–Lin28b cells exhibited enhanced tumor formation and radiation resistance in vivo. Data were presented as mean ± S.E, n=4-5 mice/group. **p<0.005; ***p<0.0005.
either a wild type (wt) or (mut) Let-7b complementary sequence were also produced; pRL-SV40 (encoding for renilla luciferase) was used for normalization. Co-transfection experiments in HEK-293 cells demonstrated significant regulation of all tested constructs by Let-7b miRNA, which appeared to correlate with the number of binding sites for each construct (Fig 3B). The regulation of these UTRs by Let-7 was specific, as mutating the seed regions almost completely abrogated this effect.

It was noteworthy that several genes involved in the IGF pathway were up-regulated in the FaDu-Lin28b cells (IGF2BP2, IGF1R, IGFBP4, and IGF2BP3). These data hence suggested that activation of this pathway might be one mechanism by which Lin28b promoted tumor survival under stress conditions. This hypothesis was addressed by culturing FaDu-GFP, FaDu-Lin28b A1, and FaDu-Lin28b D1 cells under serum-free conditions (MEM-F15 without FBS), in the presence of differing concentrations of

**Figure 2: Characterizing the miRNA and mRNA changes in FaDu-Lin28b cells.** (A) FaDu-Lin28b or FaDu-GFP cells were subjected to global miRNA expression profiling using the nCounter NanoString platform, and the normalized expression value for each miRNA were plotted for the FaDu-GFP (x-axis) vs. the FaDu-Lin28b (y-axis) cells. (B) Expression of two representative let-7 miRNAs (miR-98 and Let7-g) was assessed in two stable FaDu-Lin28b clones (A1 and D1) using single-well Taqman miRNA assay. Data were presented as mean ± S.E, n=3. (C) Venn diagram depicting the intersection between the up regulated gene list in FaDu-Lin28b cells, *in silico* predicted Let-7 gene targets, and up regulated gene list from a publicly available microarray dataset (GSE6631) on primary HNSCC. (D) Validation of a selected group of genes identified from the microarray analyses. Data were presented as mean ± S.E, n=6. *p<0.05, **p<0.005, ***p<0.0005.
recombinant IGF1 (0, 10, or 50 nM). Consistent with our hypothesis, increased viability of Lin28b-expressing cells were indeed observed in the presence of IGF1, compared to control cells (Fig 3C), corroborating that survival of Lin28b cells were driven by a functionally intact IGF1 pathway.

Expression of Lin28b, IGF2BP2, and IGF2 was associated with worse clinical outcome in HNSCC

Given that Lin28b-expressing cells were associated with increased cellular proliferation, migration, tumour formation, and radiation resistance, which appeared to be mediated through activation of the IGF pathway, we sought to determine whether Lin28b, IGF2BP2, and IGF2, bore any relationship to clinical outcome in HNSCC patients. To that end, expression levels of these three proteins was examined in the diagnostic formalin-fixed paraffin-embedded (FFPE) tumour biopsies in a selected cohort of 39 HNSCC patients wherein 19 patients had experienced a relapse; 20 have not, using immunohistochemistry (IHC). The clinical information on these patients is provided in Table 1, demonstrating that these two groups (non-relapsed vs. relapsed) were matched for important clinical parameters such as age, gender, tumour site, stage, and treatment. Representative immunostaining of HNSCC tissues by the aforementioned antibodies is shown in Supplementary Figure 2. The resulting IHC data demonstrated a significant association between higher Lin28b (cytoplasmic and nuclear), IGF2BP2 (cytoplasmic), and IGF2 (cytoplasmic).
expression with relapse in this cohort of HNSCC patients (Fig 4A). Furthermore, a significant correlation was also observed between Lin28b with both IGF2BP2 and IGF2 expression, as well as between IGF2BP2 with IGF2 expression in these HNSCC specimens (Fig 4B), strongly suggesting that the regulation of these proteins might indeed be mediated through Lin28b.

DISCUSSION

There is compelling evidence that miRNAs play important roles in mediating tumor development and progression, primarily through the regulation of their respective target genes [8, 19-34]. Adding to this complexity however, is the emerging data demonstrating that miRNAs themselves are subjected to post-transcriptional regulation by other genes. One of the best characterized examples is the negative feedback loop between the Let-7 miRNA family and Lin28, wherein Lin28 regulated Let-7 miRNA family biogenesis through interaction with TUT4 and polyuridylation [5]; and in turn, Lin28 itself is also subjected to Let-7 miRNA regulation [35]. In the current study, we observed significant down-regulation of almost the entire let-7 miRNA family in stably-transfected FaDu~Lin28b cells (Fig 2A and B). Our groups had previously profiled primary HNSCC samples, and reported the down regulation of several members of the Let-7 miRNA family, although the molecular mechanisms leading to Let-7 under-expression at that time was not elucidated [36]. Thus, our current data provide one biological explanation for the Let-7 miRNA down-regulation in HNSCC, mediated through Lin28b. While Lin28b has been reported to promote tumour progression, the precise mechanism(s) thereof has remained unclear. Previous reports have described Lin28 down-regulation of the Let-7 family, which in turn led to the increased expression of target oncogenes such as HMGA2 and RAS [17, 18]. Our data similarly identified HMGA2 up-regulation in Lin28b over-expressing cells, consistent with these previous observations.

The novelty of our current study however, relate to the identification of additional Let-7 gene targets in Lin28b over-expressing cells, with CCND2, IGF2BP2, and IGF1R being amongst the most prominent targets, experimentally corroborated by the luciferase reporter system. Furthermore, our data have unravelled yet another mechanisms by which Lin28b could promote tumour progression, namely through activation of the IGF pro-survival pathway (Fig 5). Previous reports have demonstrated regulation of IGF1R via Lin28 and Let-7 mechanisms in Lin28a transgenic mice, associated with increased body size, crown-rump length and delayed onset of puberty [7]. To the best of our knowledge, this is the first report linking regulation of the IGF pathway by the Lin28/ Let-7 axis to human cancer progression. Furthermore, we demonstrated that Lin28b expressing cells were more responsive to IGF stimulation under serum-free conditions, strongly implicating a role for Lin28b in enhancing tumour survival under stress conditions. The biological and clinical relevance of this axis was corroborated in primary HNSCC samples, wherein over-expression of these three proteins along this axis: Lin28b, IGF2BP2, and IGF2 were all significantly associated with a higher risk of relapse, highlighting the importance of this pathway in driving HNSCC progression.

The potential relevance of the IGF pathway in HNSCC has long been noted, with many opportunities for therapeutic targeting [37]. Pre-clinical evidence certainly supports this strategy [38], although a recently published Phase II clinical trial in metastatic HNSCC patients using an IGF-1R monoclonal antibody as mono-therapy has proven to be disappointing [39]. Given the complexity of this pathway, with multiple ligand and receptor interactions in epithelial cancer cells, the

| Table1: Clinical Characteristics of 39 HNSCC Patients |
|-----------------|-------------|--------------|-------------|
| Factor          | Total(n=39) | Non-recurrence(n=20) | Recurrence(n=19) |
| Age(Median, Range) | 67(50-92)  | 70(50-92)  | 63(50-87)  |
| Gender(M/F)     | 31/8        | 16/4        | 14/5        |
| Tumor site      |             |             |             |
| -Larynx         | 28          | 17          | 11          |
| -Hypopharynx    | 11          | 3           | 8           |
| Stage           |             |             |             |
| III             | 16          | 8           | 8           |
| IVA             | 22          | 12          | 10          |
| IVB             | 1           | 0           | 1           |
| Treatment Intent|             |             |             |
| RT              | 26          | 14          | 12          |
| CRT             | 13          | 5           | 8           |

RT(Radiotherapy); CRT(Chemo-Radiotherapy)
The interplay between the stroma with the malignant epithelial tissues, along with the interactions between the IGF and IGFBPs, it would have been indeed quite surprising if a single molecular therapy would have been therapeutically effective, delivered as the sole modality. Nonetheless, this current work provides additional biological insights into yet another mechanism by which this complex pathway can be activated in HNSCC.

In conclusion, we have demonstrated a novel mechanism by which Lin28b over-expression promotes tumour progression via additional Let-7 gene targets such as CCND2, IGF2BP2, and IGF1R. In turn, over-expression of Lin28b, IGF2BP2, and IGF2 in patients’ tumours at the time of diagnosis was all associated with a higher risk of relapse. Collectively, this underscores the biological importance and relevance of this complex pathway, further supporting the continued interrogation of this axis in HNSCC progression.

**Figure 4: Expression of Lin28b, IGF2BP2, and IGF2 was associated with higher risk of recurrence in primary HNSCC samples.** (A) Expression of Lin28b (nuclear, or cytoplasmic), IGF2BP2 (cytoplasmic), and IGF2 (cytoplasmic) was assessed in 39 HNSCC samples by immunohistochemistry. The relative expression level of each protein was plotted as a function of patient outcome: recurrent (R); non-recurrent (NR). (B) Positive correlations were observed between Lin28b with IGF2BP2 and IGF2, as well as between IGF2BP2 with IGF2 expression in the same cohort of HNSCC specimens as presented in A.
METHODS

Ethics statement

All tissue studies have received University Health Network institutional REB approval. All animal experiments were conducted in accordance with the guidelines of the Animal Care Committee, University Health Network.

Patients

The clinical information for the patients’ tissues used in this study has been summarized in Table 1. Patients had either laryngeal, or hypopharyngeal squamous cell carcinomas, treated for cure, with either radical radiation therapy (RT) alone, or combined with chemotherapy (Cisplatin). The median follow-up for this cohort of 39 patients was 2.8 years. The recurrent vs. non-recurrent cases were selected to be matched for age, gender, tumour site, stage, and treatment.

Cell culture

Human normal oral epithelial cells (NOE) were obtained from Celprogen (San Pedro, CA), and were cultured as previously described [40]. The HNSCC FaDu cell line was obtained from American Type Culture Collection (Manassas, VA). Cells were cultured in MEM F-15 supplemented with 10% fetal bovine serum, 100 mg/l penicillin, and 100 mg/l streptomycin at 37°C and 5% CO2. FaDu-GFP, and FaDu-Lin28b hypopharyngeal tumor cell lines were maintained under similar culture conditions.

Cloning of a Let-7 resistant Lin28b ORF expression vector

The full length Lin28b ORF (lacking the 3’ UTR and the predicted Let-7 binding sites) was amplified using the indicated primes in Supplementary Table 1, and the SuperScript III One-Step RT-PCR System with

Figure 5: Schema describing a model for Lin28b-mediated tumor progression. Over-expression of Lin28b in HNSCC cells inhibits let-7 miRNA family biogenesis. In turn, down-regulation of mature Let-7 miRNAs in Lin28b-expressing cells allows the over-expression of several Let-7 gene targets with known roles in tumor progression, such as HMGA2, and CCND2. Furthermore, down-regulation of Let-7 miRNAs in Lin28b-expressing cells also leads to up regulation of several genes in the IGF pathway such as IGF1R, and IGF2BP2, which promotes tumor survival under stress conditions.
analyses on Let-7 targets were conducted using DAVID prediction database. Gene Ontology (GO) and pathway predicted targets using the TargetScan miRNA target generated by compiling a non-redundant list of [20]. A candidate Let-7 family gene target list and the aroma.affymetrix package as described before data were normalized using R (version 2.7.1) software Microarray Center (Toronto, Canada). Gene expression array, all conducted at the University Health Network was conducted using the Affymetrix HuGene-1_0-st-v1 gene expression profiling of the same RNA preparation using the NanoString nCounter miRNA system, while FaDu, FaDu~GFP, FaDu~Lin28b and FaDu~Lin28b A1, and FaDu~Lin28b D1 cells was conducted using transfecting FaDu cells with Lin28b expression vector, followed by selection in G418 (1mg / ml), and FACS

Cell viability assay

Cell viability was assessed using the soluble tetrazolium salt (MTS) cell proliferation assay as described previously[20]. For serum-free culture experiments, 5000 FaDu, FaDu~GFP, or FaDu~Lin28b cells were cultured in MEM-F15 containing no serum, and supplemented with the indicated concentrations of recombinant IGFI (R&D Systems, Minneapolis, MN,USA). At the indicated time points, 20 ul of the MTS reagent (Promega, Madison, WI, USA) were added to each well in a 96-well plate, and absorbance was measured at λ_{492}.

Cell migration

Cell migration was assessed as also previously described [19], using the 6-well BD trans-well migration system (BD Biosciences, Franklin Lakes, NJ). Three ml RPMI supplemented with 15% FBS was added to the lower chamber, while 3x10⁶ FaDu~GFP, FaDu~Lin28b cells were re-suspended in RPMI plus 1% FBS, added to the upper chamber (2 mls). Twenty-four hours later, inserts were fixed and stained using SIEMENNS DIFF-QUICK stain set (Siemens Healthcare Diagnostics, Deerfield, IL), and the number of migrating cells in five 10x fields was then quantified.

Micro-RNA and gene expression profiling

Global micro-RNA expression profiling of FaDu~Lin28b and FaDu~GFP cells was conducted using the NanoString nCounter miRNA system, while gene expression profiling of the same RNA preparation was conducted using the Affymetrix HuGene-1 0-st-v1 array, all conducted at the University Health Network Microarray Center (Toronto, Canada). Gene expression data were normalized using R (version 2.7.1) software and the aroma.affymetrix package as described before [20]. A candidate Let-7 family gene target list was generated by compiling a non-redundant list of in silico predicted targets using the TargetScan miRNA target prediction database. Gene Ontology (GO) and pathway analyses on Let-7 targets were conducted using DAVID Bioinformatics Database functional-annotation tools, as we have previously described [19, 41].

qRT-PCR for mRNA and miRNA expression

QRT-PCR analyses were performed using the ABI PRISM 7900 Sequence Detection System (Applied Biosystems Inc., Foster City, CA, USA). The primer sequences used in this study are listed in Supplementary Table 1. Total RNA was isolated using the Norgen total RNA purification kit (Norgen Biotek Corporation, Canada). Reverse transcription was performed using SuperScript III Reverse Transcriptase (Invitrogen Corp.) according to the manufacturer’s recommendations. The relative fold change in RNA expression was calculated using the 2^{ΔΔCt} method, where the average of ΔCt values for the amplicon of interest was normalized to that of an endogenous gene (GAPDH), compared with control specimens. Single-well miRNA PCR were conducted using Taqman MicroRNA PCR, as we have previously reported [19].

Immunoblotting

Immunoblotting was done as described before [42]. NOE, FaDu, FaDu~Lin28bA1, and FaDu~Lin28b D1 cells were collected and lysed in 1 M Tris-HCl (pH 8), 5 M NaCl, and 1% NP40 plus protease inhibitor cocktail (Roche Diagnostics, Quebec, Canada). Protein concentration was determined using the Bio-Rad Detergent-Compatible Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA). In total, 20µg of protein were loaded onto 10% Tris-glycine protein gels (Invitrogen) for electrophoresis. The protein was then transferred onto a nitrocellulose membrane using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad) and blocked using TBST (0.1% Tween-20 plus 5% fat-free dry milk). The membrane was probed with anti-Lin28b (1:100 dilution; Abcam# ab71415), and anti-GAPDH (Abcam, Cambridge, MA, USA) antibodies, as previously described [41].

Luciferase Reporter Assay

A reporter vector (pMir-Report, ABI) carrying the predicted Let-7 binding site(s) from each 3’ UTR was constructed using partially complementary primer pairs as indicated in Supplementary Table 1 and Figure 3, using Amplitaq gold DNA polymerase (Applied Biosystems Inc, Foster City, CA). IGF2BP2 has two putative Let-7 binding sites; IGF1R and CCND2 each have three putative binding sites, while HMGA2 has six putative binding sites. As positive control, we constructed a vector carrying the full length complementary sequence to Let-7b miRNA. A mutant version of each reporter plasmid was
generated by mutating the seed region for the let-7 miRNA family using the indicated primers in Supplementary Table 1. All regions were subsequently cloned into the SPE I and HIND III sites downstream of the firefly luciferase gene in the pMIR-REPORT vector (Applied Biosystems Inc, Foster City, CA). To assess the direct interaction between Let-7 miRNA family and the 3’UTR from the aforementioned targets, HEK-293 cells were transfected with 100 nM of pre-miR-ctrl, or pre-miR-Let-7b. Six hours later, cells were co-transfected with 100 ng of pMIR-REPORT carrying either wt or mutant 3’ UTR sequences, along with 20 ng of pRL-SV40 vector (Promega) carrying the Renilla luciferase gene. Transfection experiments were conducted using Lipofectamine 2000 (Invitrogen). At 48 hrs post-transfection, luciferase activity was measured using the Dual-Glo luciferase assay system (Promega). Firefly luciferase activity was then normalized to that of Renilla luciferase.

In vivo experiments

For tumor formation assay, 5x10^5 FaDu~GFP or FaDu~Lin28b cells were injected intramuscular (IM) into the left gastrocnemius muscle of 6–8-week-old female SCID mice. Once tumours started to grow, half of the tumor-bearing mice were exposed to 5 Gy local RT as described before [43]. Briefly, mice were immobilized in a Lucite box and the tumor-bearing leg was exposed to 225 kV (13 mA) at a dose rate of 3.37 Gy/min (X-RAD 225C Biological X-Ray Irradiator; Precision X-Ray, North Branford, CT). Tumor growth was monitored by measuring tumor plus leg diameter as described previously [41].

Immunohistochemistry

Lin28b, IGF2BP2, and IGF2 immunohistochemistry evaluations were performed on 4-um FFPE tumor sections using microwave antigen retrieval, in combination with the LSAB+System-HRP (Dako North America, Carpinteria, CA, USA). Detection of these proteins utilized rabbit anti-Lin28b (1:50 dilution; Abcam# ab71415), anti-IGF2BP2 (1:500 dilution, Novus Biological), and anti-IGF2 (1:250 dilution, Abcam# ab9574) antibodies. Expression was scored as previously described [20]. Briefly, for cytoplasmic staining, the intensity of tumor cells staining was evaluated as 0, 1, 2 and 3. Tumor nuclear staining was also calculated on 3 staining fields with at least 300 tumor cells, as 0, 1: <25%, 2: 25-50%; 3: >50%.

Statistical analysis

Statistical analyses and graphing were performed using Microsoft excel 2007 and Graphpad Prism 5.0 software (Graphpad software, San Diego, CA, USA).

ACKNOWLEDGEMENT

This work has been supported by fund from the Ontario Institute of Cancer Research, the Canadian Institutes of Health Research, and the Dr. Mariano Elia Chair in Head and Neck Oncology. We also gratefully acknowledge the philanthropic support from the Wharton Family, Joe’s Team, and Gordon Tozer. Nehad Alajez is a recipient of a scholarship from the Terry Fox Foundation Strategic Training Initiative for Excellence in Radiation Research of the 21st Century (EIRR21) at the Canadian Institutes of Health Research (CIHR). Support is also provided from the Campbell Family Institute for Cancer Research and the Ministry of Health and Long-term Planning.

REFERENCE

1. Richards M, Tan SP, Tan JH, Chan WK and Bongso A. The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells. 2004; 22(1):51-64.
2. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II and Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858):1917-1920.
3. Viswanathan SR, Daley GQ and Gregory RI. Selective blockade of microRNA processing by Lin28. Science. 2008; 320(5872):97-100.
4. Heo I, Joo C, Cho J, Ha M, Han J and Kim VN. Lin28 mediates the terminal uridylation of let-7 precursor microRNA. Mol Cell. 2008; 32(2):276-284.
5. Heo I, Joo C, Kim YK, Ha M, Yoon MJ, Cho J, Yeom KH, Han J and Kim VN. TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell. 2009; 138(4):696-708.
6. Hagan JP, Piskounova E and Gregory RI. Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat Struct Mol Biol. 2009; 16(10):1021-1025.
7. Zhu H, Shah S, Shyh-Chang N, Shinoda G, Einhorn WS, Viswanathan SR, Takeuchi A, Grasemann C, Rinn JL, Lopez MF, Hirschhorn JN, Palmert MR and Daley GQ. Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet. 42(7):626-630.
8. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O’Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009; 41(7):843-848.
9. Saiki Y, Ishimaru S, Mimori K, Takatsuno Y, Nagahara M, Ishii H, Yamada K and Mori M. Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol. 2009; 16(9):2638-2644.

10. Iliopoulos D, Hirsch HA and Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009; 139(4):693-706.

11. King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS and Iliopoulos D. A transcriptional switch between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007; 315(5818):1576-1579.

12. Peng S, Maihle NJ and Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene. 2009; 29(14):2153-2159.

13. Oh JS, Kim JJ, Byun JY and Kim IA. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys. 76(1):5-8.

14. Yang X, Lin X, Zhong X, Kaur S, Li N, Liang S, Lassus H, Wang L, Katsaros D, Montone K, Zhao X, Zhang Y, Butzow R, Coukos G and Zhang L. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res. 70(22):9463-9472.

15. Meirelles K, Benedict LA, Dombkowski D, Pepin D, Preffer FI, Teixeira J, Tanwar PS, Young RH, Maughlin DT, Donahoe PK and Wei X. Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci U S A. 109(7):2358-2363.

16. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP and Krueger LJ. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007; 67(20):9762-9770.

17. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack FJ. RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-647.

18. Mayr C, Hemann MT and Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007; 315(5818):1576-1579.

19. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, O’Sullivan B and Liu FF. miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway. Cancer Res. 2011; 71(6):2381-2391.

20. Alajez N, Shi W, Hui A, Bruce J, Lenarduzzi M, Ito E, Yue S, O’Sullivan B and Liu F. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death & Disease. 2010; 1(10):e85.

21. Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P, Valeri B, Libra M, Barbaresci M, Raspagliesi F, Mezzananza D and Canevari S. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget. 2011; 2(12):1265-1278.

22. Schetter AJ and Harris CC. MicroRNAs as molecular classifiers for cancer. Cell Cycle. 2011; 10(17):2827-2828.

23. Del Barco S, Vazquez-Martín A, Cufi S, Oliveras-Ferramos C, Bosch-Barrera J, Joven J, Martin-Castillo B and Menendez JA. Metformin: multi-faceted protection against cancer. Oncotarget. 2011; 2(12):896-917.

24. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S and De Marzo AM. Myc enforces overexpression of E2H2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2011; 2(9):669-683.

25. Heasman SA, Zaitseva L, Bowles KM, Rushworth SA and Macewan DJ. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapy is mediated by haem oxygenase-1. Oncotarget. 2011; 2(9):658-668.

26. Mavrakis KJ, Leslie CS and Wendel HG. Cooperative control of tumor suppressor genes by a network of oncogenic microRNAs. Cell Cycle. 2011; 10(17):2845-2849.

27. Erkan EP, Breakefield XO and Saydam O. miRNA signature of schwannomas: possible role(s) of “tumor suppressor” miRNAs in benign tumors. Oncotarget. 2011; 2(3):265-270.

28. Ory B and Ellisen LW. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity. Oncotarget. 2011; 2(3):259-264.

29. Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng HF, Akbari Moqadam F, Oude Vrielink JA, Agami R, Den Boer ML, Grander D and Sangfelt O. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle. 2011; 10(13):2172-2183.

30. Nohata N, Sone Y, Hanazawa T, Fuse M, Kikawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Shozu M, Okamoto Y and Seki N. miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget. 2011; 2(1):29-42.

31. Tacutu R, Budovsky A, Yanai H and Fraifeld VE. Molecular links between cellular senescence, longevity and age-related diseases - a systems biology perspective. Aging (Albany NY). 2011; 3(12):1178-1191.

32. Li X, Khanna A, Li N and Wang E. Circulatory miR34a as an RNA-based, noninvasive biomarker for brain aging. Aging (Albany NY). 2011; 3(10):985-1002.

33. Melo SA and Esteller M. A precursor microRNA in a cancer cell nucleus: get me out of here! Cell Cycle. 2011;
34. Peck B and Schulze A. A role for the cancer-associated miR-106b-25 cluster in neuronal stem cells. Aging (Albany NY). 2011; 3(4):329-331.

35. Moss EG and Tang L. Conservation of the heterochronic regulator Lin-28, its developmental expression and microRNA complementary sites. Dev Biol. 2003; 258(2):432-442.

36. Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W, Perez-Ordonez B, Jurisica I, O’Sullivan B, Waldron J, Gullane P, Cummings B and Liu FF. Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res. 2010; 16(4):1129-1139.

37. Rosenzweig SA and Atreya HS. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochemical pharmacology. 80(8):1115-1124.

38. Galer CE, Corey CL, Wang Z, Younes MN, Gomez† Rivera F, Jasser SA, Ludwig DL, Elâ€ Naggar AK, Weber RS and Myers JN. Dual inhibition of epidermal growth factor receptor and insulinâ€ like growth factor receptor I: Reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head & neck. 33(2):189-198.

39. Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, Bompas E, Moxhon A, Mignon L, Guigay J and Knoops L. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Annals of Oncology.

40. Alajez NM, Mocanu JD, Shi W, Chia MC, Breitbach CJ, Hui AB, Knowles S, Bell JC, Busson P, Takada K, Lo KW, O’Sullivan B, Gullane P and Liu FF. Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma. Clin Cancer Res. 2008; 14(15):4891-4897.

41. Alajez NM, Shi W, Hui AB, Yue S, Ng R, Lo KW, Bastianutto C, O’Sullivan B, Gullane P and Liu FF. Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy. Cell Death Differ. 2009; 16(11):1469-1479.

42. Shi W, Alajez NM, Bastianutto C, Hui ABY, Mocanu JD, Ito E, Busson P, Lo KW, Ng R and Waldron J. Significance of Plk1 regulation by miRâ€ 100 in human nasopharyngeal cancer. International Journal of Cancer. 126(9):2036-2048.

43. Ito E, Yue S, Moriyama EH, Hui AB, Kim I, Shi W, Alajez NM, Bhogal N, Li G, Datti A, Schimmer AD, Wilson BC, Liu PP, Durocher D, Neel BG, O’Sullivan B, et al. Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci Transl Med. 2011; 3(67):67ra67.